⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies (LS2.005)

Jiwon Oh Amit Bar-Or Gavin Giovannoni Maria Pia Sormani Martin S. Weber Sharon Stoll Jacqueline Nicholas H.-Christian von Büdingen Marquita Decker-Palmer Anastasia Loukitcheva Miriam Triyatni Nan Hu John N. Ratchford Julie Napieralski Alexandra Goodyear L Kappos Stephen Hauser

View at Publisher

Ask AI

Bookmark

Share

Key Points

This study aims to compare the efficacy and safety of fenebrutinib and teriflunomide in treating relapsing multiple sclerosis.
Evaluated adults with relapsing multiple sclerosis
Compared efficacy and safety profiles of fenebrutinib and teriflunomide
Fenebrutinib demonstrated superior efficacy compared to teriflunomide in reducing relapse rates.
Safety profiles were comparable between the two treatments, with no significant differences in adverse events.

Implication

Evaluates efficacy and safety of fenebrutinib in relapsing multiple sclerosis, indicating potential treatment options.

Abstract

To evaluate the efficacy and safety of fenebrutinib vs teriflunomide in adults with relapsing multiple sclerosis (RMS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oh et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f056104 https://doi.org/10.1212/wnl.0000000000217910

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study (S40.004)Late-Phase Clinical Trial · 2026 · 1 citations
2The Safety Profile of Fenebrutinib in Patients with Multiple Sclerosis Is Consistent with Those in Previously Studied Autoimmune Indications (P9-6.012)2024 · 2 citations
3Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004)2024 · 2 citations
4Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trialsBlinded Clinical Trial · 2026
5A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib and Effect on the QT/QTc Interval in Healthy Participants.RCT · 2026 · 1 citations

More related papers

A Two-part, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib (Part A) and the Effect of Fenebrutinib on the QT/QTc Interval in Healthy Participants (Part B) (P10-6.011)2024
Teriflunomide for the Treatment of Relapsing Multiple Sclerosis2013
Long‐Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries2024

More from Neurology

Antidopaminergic Medications and Clinical Outcomes in Huntington DiseaseThu,
Recanalization After Acute Cervical Artery DissectionTue,